Literature DB >> 15106020

Inhaled nitric oxide for ARDS due to sickle cell disease.

Michael Oppert1, Achim Jörres, Detlef Barckow, Kai-Uwe Eckardt, Ulrich Frei, Udo Kaisers.   

Abstract

A 36-year-old male with a known history of sickle cell disease (SCD) and acute chest syndrome (ACS) was treated in our hospital. Gas exchange deteriorated and the patient was transferred to our intensive care unit (ICU). Low dose inhaled nitric oxide (iNO) during pressure controlled mechanical ventilation (pcMV) induced a clinically relevant increase in arterial oxygenation. The patient was weaned from pcMV after five days and discharged home 14 days later. ACS evolving to acute respiratory distress syndrome (ARDS) is a rare but severe complication. In ACS iNO should be considered a beneficial therapeutic option.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15106020     DOI: 2004/11/smw-10521

Source DB:  PubMed          Journal:  Swiss Med Wkly        ISSN: 0036-7672            Impact factor:   2.193


  8 in total

Review 1.  Redox-dependent impairment of vascular function in sickle cell disease.

Authors:  Mutay Aslan; Bruce A Freeman
Journal:  Free Radic Biol Med       Date:  2007-08-31       Impact factor: 7.376

2.  Inhaled nitric oxide for acute chest syndrome in adult sickle cell patients: a randomized controlled study.

Authors:  B Maitre; M Djibre; S Katsahian; A Habibi; K Stankovic Stojanovic; M Khellaf; I Bourgeon; F Lionnet; A Charles-Nelson; L Brochard; F Lemaire; F Galacteros; C Brun-Buisson; M Fartoukh; A Mekontso Dessap
Journal:  Intensive Care Med       Date:  2015-10-02       Impact factor: 17.440

3.  Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: a randomized controlled trial.

Authors:  Mark T Gladwin; Gregory J Kato; Debra Weiner; Onyinye C Onyekwere; Carlton Dampier; Lewis Hsu; R Ward Hagar; Thomas Howard; Rachelle Nuss; Maureen M Okam; Carole K Tremonti; Brian Berman; Anthony Villella; Lakshmanan Krishnamurti; Sophie Lanzkron; Oswaldo Castro; Victor R Gordeuk; Wynona A Coles; Marlene Peters-Lawrence; James Nichols; Mary K Hall; Mariana Hildesheim; William C Blackwelder; James Baldassarre; James F Casella
Journal:  JAMA       Date:  2011-03-02       Impact factor: 56.272

4.  Nitric oxide reduces sickle hemoglobin polymerization: potential role of nitric oxide-induced charge alteration in depolymerization.

Authors:  Tohru Ikuta; Hemant S Thatte; Jay X Tang; Ishita Mukerji; Kelly Knee; Kenneth R Bridges; Sabina Wang; Pedro Montero-Huerta; Ratan Mani Joshi; C Alvin Head
Journal:  Arch Biochem Biophys       Date:  2011-03-30       Impact factor: 4.013

5.  Nitric oxide pathology and therapeutics in sickle cell disease.

Authors:  Daniel B Kim-Shapiro; Mark T Gladwin
Journal:  Clin Hemorheol Microcirc       Date:  2018       Impact factor: 2.375

Review 6.  Sickle cell disease: new opportunities and challenges in Africa.

Authors:  J Makani; S F Ofori-Acquah; O Nnodu; A Wonkam; K Ohene-Frempong
Journal:  ScientificWorldJournal       Date:  2013-09-19

7.  Hydroxyurea improves nitric oxide bioavailability in humanized sickle cell mice.

Authors:  Crystal M Taylor; Malgorzata Kasztan; Randee Sedaka; Patrick A Molina; Luke S Dunaway; Jennifer S Pollock; David M Pollock
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2021-02-24       Impact factor: 3.619

8.  Glycosylation inhibitors efficiently inhibit P-selectin-mediated cell adhesion to endothelial cells.

Authors:  Pushpankur Ghoshal; Mythilypriya Rajendran; Nadine Odo; Tohru Ikuta
Journal:  PLoS One       Date:  2014-06-19       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.